- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cystic fibrosis
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 March 2023 PBAC Meetings - (PDF 1.1MB)
- Public Summary Document (PSD) November 2022 March 2023 PBAC Meetings - (Word 381KB)
Related Public Summary Documents
Elexacaftor with tezacaftor and with ivacaftor, and ivacaftor –March 2023
